Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer

This study is testing whether adding camrelizumab (an immunotherapy drug) to chemotherapy before surgery can improve outcomes for young women with early-stage cervical cancer (stage IB1) who want to preserve their fertility. **You may be eligible if...** - You have been diagnosed with stage IB1 cervical squamous cell carcinoma (confirmed by biopsy) - Your tumor's PD-L1 test is POSITIVE (combined positive score ≥ 1) - You are between 18 and 45 years old and have a strong desire to have children in the future - You are in good general health (ECOG ≤ 1) and your blood counts and organ function meet minimum requirements **You may NOT be eligible if...** - Your cervical cancer is a different histological type (not squamous cell carcinoma) - Your tumor is PD-L1 negative - You do not wish to preserve fertility - You have poor organ function or blood count issues Talk to your doctor to see if this trial is right for you.